Size | Price | |
---|---|---|
500mg | ||
1g | ||
Other Sizes |
ln Vitro |
Ac13 (0-10 μM, 3 h) has an anti-tumor effect, with GI50 of 588, 86, and 6.6 nM in K562, HL-60, and CCRF-CEM cells, inhibiting AURKA autophosphorylation and cell viability in a dose-dependent manner [1]. Ac13 (10 μM, 1 h)-induced K162 acetylation of endogenous AURKA is reversible in HCT116 cells expressing SIRT3 [1].
|
---|---|
Cell Assay |
Western Blot Analysis[1]
Cell Types: K562 Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3, 10 μM; 2 μM Incubation Duration: 3 h for 0-10 μM; 2 μM for 1h Experimental Results: Inhibited endogenous autophosphorylation of AURKA (T288) in a dose-dependent manner at 0-10 μM. K562 cell viability and AURKA autophosphorylation could be continuously inhibited after washout test. Induced potent acetylation of endogenous AURKA, and endogenous AURKA acetylated at K162 in K562 cells treated with Ac13 (2 μM, 1 h) was blocked by X1 (covalently modifiable lysine) (20 μM, 1 h). Ac13 (20 μM, 1 h) effectively blocked XO44 (covalently modifiable lysine) labeling of K562/HL-60 cells and could maintain the selectivity of VX-680 (a noncovalent inhibitor of AURKA). Cell Cytotoxicity Assay[1] Cell Types: HCT116 and HCT116 successfully expressed SIRT3 Concentration: 10 μM Incubation Duration: 1h Experimental Results: Induced acetylation of AURKA in HCT116 cells, inhibited endogenous AURKA activity and p53 degradation. Abolished AURKA and restored the kinase activity of K162-acetylated AURKA as well as p53 phosphorylation and degradation after successful expression of SIRT3. |
References |
Molecular Formula |
C28H32FN9O2
|
---|---|
Molecular Weight |
545.61
|
Appearance |
Typically exists as solids at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8328 mL | 9.1641 mL | 18.3281 mL | |
5 mM | 0.3666 mL | 1.8328 mL | 3.6656 mL | |
10 mM | 0.1833 mL | 0.9164 mL | 1.8328 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.